The Need for Pediatric Formulations to Treat Children with HIV
Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important ca...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2016/1654938 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546145208893440 |
|---|---|
| author | Adrienne F. Schlatter Andrew R. Deathe Rachel C. Vreeman |
| author_facet | Adrienne F. Schlatter Andrew R. Deathe Rachel C. Vreeman |
| author_sort | Adrienne F. Schlatter |
| collection | DOAJ |
| description | Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence. |
| format | Article |
| id | doaj-art-8d0261736247420eadefcc0556dec5f0 |
| institution | Kabale University |
| issn | 2090-1240 2090-1259 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | AIDS Research and Treatment |
| spelling | doaj-art-8d0261736247420eadefcc0556dec5f02025-02-03T07:23:50ZengWileyAIDS Research and Treatment2090-12402090-12592016-01-01201610.1155/2016/16549381654938The Need for Pediatric Formulations to Treat Children with HIVAdrienne F. Schlatter0Andrew R. Deathe1Rachel C. Vreeman2Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USADepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USADepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USAOver 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.http://dx.doi.org/10.1155/2016/1654938 |
| spellingShingle | Adrienne F. Schlatter Andrew R. Deathe Rachel C. Vreeman The Need for Pediatric Formulations to Treat Children with HIV AIDS Research and Treatment |
| title | The Need for Pediatric Formulations to Treat Children with HIV |
| title_full | The Need for Pediatric Formulations to Treat Children with HIV |
| title_fullStr | The Need for Pediatric Formulations to Treat Children with HIV |
| title_full_unstemmed | The Need for Pediatric Formulations to Treat Children with HIV |
| title_short | The Need for Pediatric Formulations to Treat Children with HIV |
| title_sort | need for pediatric formulations to treat children with hiv |
| url | http://dx.doi.org/10.1155/2016/1654938 |
| work_keys_str_mv | AT adriennefschlatter theneedforpediatricformulationstotreatchildrenwithhiv AT andrewrdeathe theneedforpediatricformulationstotreatchildrenwithhiv AT rachelcvreeman theneedforpediatricformulationstotreatchildrenwithhiv AT adriennefschlatter needforpediatricformulationstotreatchildrenwithhiv AT andrewrdeathe needforpediatricformulationstotreatchildrenwithhiv AT rachelcvreeman needforpediatricformulationstotreatchildrenwithhiv |